# A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

> **NCT01491737** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 258 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pertuzumab
- **DRUG:** Trastuzumab
- **DRUG:** Aromatase Inhibitor
- **DRUG:** Induction Chemotherapy

## Key facts

- **NCT ID:** NCT01491737
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-17
- **Primary completion:** 2016-03-17
- **Final completion:** 2019-11-14
- **Target enrollment:** 258 (ACTUAL)
- **Last updated:** 2020-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01491737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01491737, "A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01491737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*